The role of estrogens and related compounds in the management of primary hyperparathyroidism.
Marcus
Robert
R
USMD Endocrinology, Eli Lilly Corporation, Indianapolis, Indiana 46221-2001, USA.
D015519:Bone Density / Q000187:drug effects; D002118:Calcium / Q000819:agonists / Q000097:blood; D004967:Estrogens / Q000502:physiology* / Q000627:therapeutic use*; D006801:Humans; D006961:Hyperparathyroidism / Q000097:blood / Q000188:drug therapy*; D010281:Parathyroid Hormone / Q000097:blood; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use
D004967:Estrogens; D010281:Parathyroid Hormone; D020845:Selective Estrogen Receptor Modulators; D020849:Raloxifene Hydrochloride; D002118:Calcium